# Mineralocorticoid (Aldosterone) Receptor Antagonists (Potassium Sparing Diuretics)

## Examples

- `spironolactone`
- `eplerenone`

## Mechanism of Action (MOA)

- Act on the **late distal tubule and collecting duct**.
- **Competitively block aldosterone (mineralocorticoid) receptors** in principal cells.
- This → ↓ synthesis of:
  - **Epithelial Na⁺ channels (ENaC)** on the luminal side
  - **Na⁺/K⁺-ATPase pumps** on the basolateral side

- Result:
  - ↓ Na⁺ reabsorption
  - ↓ K⁺ and H⁺ excretion
  - Mild diuretic effect but **strong K⁺ retention**

![MRA Acting](/pharmacology/cvs/anti-hypertensives/diuretics/mra-acting.png)

## Pharmacodynamics (Effects)

- **Mild diuresis** (only ~2% of filtered Na⁺).
- **Potassium-sparing** — prevents hypokalemia.
- **↓ Blood pressure** (due to natriuresis and volume reduction).
- **Anti-aldosterone (anti-fibrotic, anti-remodeling)** → ↓ cardiac remodeling and mortality in CHF.
- `eplerenone` is **more selective** → fewer endocrine side effects.

## Pharmacokinetics

| **Property**         | **Notes**                                                                                 |
| :------------------- | :---------------------------------------------------------------------------------------- |
| **Absorption**       | Oral; well absorbed.                                                                      |
| **Onset / Duration** | Slow onset (because gene transcription effect) — takes several days to act.               |
| **Metabolism**       | `spironolactone` → active metabolite (`canrenone`). `eplerenone` → metabolized by CYP3A4. |
| **Elimination**      | Renal and biliary.                                                                        |

## Indications

- **Primary (essential) hypertension** — _add-on therapy_, especially for resistant HTN.
- **Heart failure (HFrEF)** — improves survival (RALES, EPHESUS trials).
- **Primary hyperaldosteronism (Conn’s syndrome)** — diagnostic & therapeutic.
- **Secondary hyperaldosteronism** — cirrhosis, nephrotic syndrome, CHF.
- **Edema** due to hepatic or cardiac causes.
- **Polycystic ovary syndrome (PCOS)** — `spironolactone` for anti-androgen effect.

## Adverse Effects

| **Effect**                                                                              | **Mechanism / Notes**                                                                                                  |
| :-------------------------------------------------------------------------------------- | :--------------------------------------------------------------------------------------------------------------------- |
| **Hyperkalemia**                                                                        | Due to ↓ K⁺ excretion (major risk).                                                                                    |
| **Metabolic acidosis**                                                                  | ↓ H⁺ secretion.                                                                                                        |
| **Endocrine effects (spironolactone)**                                                  | Gynecomastia, menstrual irregularities, impotence, testicular atrophy (antiandrogenic, progesterone agonist activity). |
| **GI upset, nausea, lethargy.**                                                         |                                                                                                                        |
| **Eplerenone** — fewer hormonal side effects (selective aldosterone receptor blockade). |                                                                                                                        |

## Cautions

- **Renal impairment** (↑ K⁺ risk).
- **Concurrent ACEI, ARB, or ENaC blockers** → additive hyperkalemia.
- **Elderly patients** — decreased renal clearance.
- **Monitor serum K⁺ and creatinine** regularly.

## Contraindications

- **Hyperkalemia (>5 mmol/L).**
- **Severe renal failure / anuria.**
- **Addison’s disease (aldosterone deficiency).**
- **Concomitant potassium supplements.**

## Key Points

- **`Spironolactone`**: less selective, more hormonal side effects, but cheaper.
- **`Eplerenone`**: selective, safer in males, but more expensive.
- Both improve **survival in heart failure** and are recommended in **resistant hypertension** (4th-line drug).
- Effect **develops slowly (over days)** but **lasts long**.

✅ **Summary Comparison (quick recall):**

| **Feature**            | **Spironolactone**                         | **Eplerenone**         |
| :--------------------- | :----------------------------------------- | :--------------------- |
| Receptor selectivity   | Non-selective (also androgen/progesterone) | Highly selective       |
| Onset                  | Slow (2–3 days)                            | Slow                   |
| Endocrine side effects | Common                                     | Minimal                |
| CYP3A4 metabolism      | Minimal                                    | Yes (CYP3A4 substrate) |
| Cost                   | Low                                        | Higher                 |

Would you like me to continue next with **Sympatholytic Drugs (Adrenergic Inhibitors)** next — starting with **Centrally Acting Agents (`methyldopa`, `clonidine`)?**
